Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

541 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Vaso-occlusive crises and costs of sickle cell disease in patients with commercial, Medicaid, and Medicare insurance - the perspective of private and public payers.
Shah NR, Bhor M, Latremouille-Viau D, Kumar Sharma V, Puckrein GA, Gagnon-Sanschagrin P, Khare A, Kumar Singh M, Serra E, Davidson M, Xu L, Guerin A. Shah NR, et al. Among authors: guerin a. J Med Econ. 2020 Nov;23(11):1345-1355. doi: 10.1080/13696998.2020.1813144. Epub 2020 Sep 9. J Med Econ. 2020. PMID: 32815766 Free article.
Comparison of survival and hospitalization rates between Medicare patients with advanced NSCLC treated with bevacizumab-carboplatin-paclitaxel and carboplatin-paclitaxel: a retrospective cohort study.
Langer C, Ravelo A, Hazard SJ, Guerin A, Ionescu-Ittu R, Latremouille-Viau D, Wu EQ, Ramalingam S. Langer C, et al. Among authors: guerin a. Lung Cancer. 2014 Dec;86(3):350-7. doi: 10.1016/j.lungcan.2014.09.017. Epub 2014 Sep 30. Lung Cancer. 2014. PMID: 25439437
Treatment patterns, overall survival, healthcare resource use and costs in elderly Medicare beneficiaries with chronic myeloid leukemia using second-generation tyrosine kinase inhibitors as second-line therapy.
Smith BD, Liu J, Latremouille-Viau D, Guerin A, Fernandez D, Chen L. Smith BD, et al. Among authors: guerin a. Curr Med Res Opin. 2016 May;32(5):817-27. doi: 10.1185/03007995.2016.1140030. Epub 2016 Feb 10. Curr Med Res Opin. 2016. PMID: 26743563
Nilotinib versus dasatinib as second-line therapy in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase who are resistant or intolerant to imatinib: a cost-effectiveness analysis based on real-world data.
Li N, Yang X, Fan L, Totev T, Guerin A, Chen L, Bhattacharyya S, Joseph G. Li N, et al. Among authors: guerin a. J Med Econ. 2017 Apr;20(4):328-336. doi: 10.1080/13696998.2016.1261032. Epub 2016 Dec 2. J Med Econ. 2017. PMID: 27841717 Free article.
Health Care Resource Utilization and Costs in Patients with Chronic Myeloid Leukemia with Better Adherence to Tyrosine Kinase Inhibitors and Increased Molecular Monitoring Frequency.
Latremouille-Viau D, Guerin A, Gagnon-Sanschagrin P, Dea K, Cohen BG, Joseph GJ. Latremouille-Viau D, et al. Among authors: guerin a. J Manag Care Spec Pharm. 2017 Feb;23(2):214-224. doi: 10.18553/jmcp.2017.23.2.214. J Manag Care Spec Pharm. 2017. PMID: 28125373 Free PMC article.
When considering the indirect effect of qPCR test frequency through TKI adherence, an increase of 1 qPCR test combined with an increase in TKI adherence by 2.2 percentage points was associated with a greater reduction of inpatient days from 13.0% to 15.2%, ER visits from 8 …
When considering the indirect effect of qPCR test frequency through TKI adherence, an increase of 1 qPCR test combined with an increase in T …
Assessment of costs associated with adverse events in patients with cancer.
Wong W, Yim YM, Kim A, Cloutier M, Gauthier-Loiselle M, Gagnon-Sanschagrin P, Guerin A. Wong W, et al. Among authors: guerin a. PLoS One. 2018 Apr 13;13(4):e0196007. doi: 10.1371/journal.pone.0196007. eCollection 2018. PLoS One. 2018. PMID: 29652926 Free PMC article.
Institutionalization risk and costs associated with agitation in Alzheimer's disease.
Cloutier M, Gauthier-Loiselle M, Gagnon-Sanschagrin P, Guerin A, Hartry A, Baker RA, Duffy R, Gwin K, Sanon Aigbogun M. Cloutier M, et al. Among authors: guerin a. Alzheimers Dement (N Y). 2019 Nov 23;5:851-861. doi: 10.1016/j.trci.2019.10.004. eCollection 2019. Alzheimers Dement (N Y). 2019. PMID: 31799369 Free PMC article.
Economic burden of peanut allergy in pediatric patients with evidence of reactions to peanuts in the United States.
Blaiss MS, Meadows JA, Yu S, Robison DR, Hass SL, Norrett KE, Guerin A, Latremouille-Viau D, Tilles SA. Blaiss MS, et al. Among authors: guerin a. J Manag Care Spec Pharm. 2021 Apr;27(4):516-527. doi: 10.18553/jmcp.2021.20389. Epub 2021 Jan 20. J Manag Care Spec Pharm. 2021. PMID: 33470880 Free PMC article.
Yu and Tilles are employees of Aimmune Therapeutics, a Nestle Health Science company. Robison and Norrett were employees of Aimmune Therapeutics at the time this study was conducted. Blaiss, Meadows, and Hass provided paid consulting services to Aimmune Therapeutics. Gu …
Yu and Tilles are employees of Aimmune Therapeutics, a Nestle Health Science company. Robison and Norrett were employees of Aimmune T …
Impact of agitation in long-term care residents with dementia in the United States.
Fillit H, Aigbogun MS, Gagnon-Sanschagrin P, Cloutier M, Davidson M, Serra E, Guérin A, Baker RA, Houle CR, Grossberg G. Fillit H, et al. Among authors: guerin a. Int J Geriatr Psychiatry. 2021 Dec;36(12):1959-1969. doi: 10.1002/gps.5604. Epub 2021 Aug 27. Int J Geriatr Psychiatry. 2021. PMID: 34286877 Free PMC article.
Economic burden of attention-deficit/hyperactivity disorder among adults in the United States: a societal perspective.
Schein J, Adler LA, Childress A, Gagnon-Sanschagrin P, Davidson M, Kinkead F, Cloutier M, Guérin A, Lefebvre P. Schein J, et al. Among authors: guerin a. J Manag Care Spec Pharm. 2022 Feb;28(2):168-179. doi: 10.18553/jmcp.2021.21290. Epub 2021 Nov 22. J Manag Care Spec Pharm. 2022. PMID: 34806909
Excess costs incurred by adults with ADHD during 2018 were evaluated from a societal perspective; per-patient costs were extrapolated to the national level. RESULTS: An estimated 8.7 million adults live with ADHD in the United States, resulting in a total societal e …
Excess costs incurred by adults with ADHD during 2018 were evaluated from a societal perspective; per-patient costs were extrapolated …
Costs associated with the administration of erythropoiesis-stimulating agents for the treatment of anemia in patients with non-dialysis-dependent chronic kidney disease: a US societal perspective.
Gauthier-Loiselle M, Michalopoulos SN, Cloutier M, Serra E, Bungay R, Szabo E, Guérin A. Gauthier-Loiselle M, et al. Among authors: guerin a. J Manag Care Spec Pharm. 2021 Dec;27(12):1703-1713. doi: 10.18553/jmcp.2021.27.12.1703. J Manag Care Spec Pharm. 2021. PMID: 34818094 Free PMC article.
CONCLUSIONS: The needle-based administration of ESAs in patients with NDD-CKD is associated with a substantial economic burden. The introduction of an oral treatment has the potential to result in important cost savings from a societal perspective. ...Gauthier-Loise …
CONCLUSIONS: The needle-based administration of ESAs in patients with NDD-CKD is associated with a substantial economic burden. The i …
541 results